STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Non-peptide

Astaxanthin

Also known as

ASX · AST · AX · Astaxanthine · Astaxanthin (biohacking adjacency) · Haematococcus pluvialis extract · Haematococcus lacustris extract · Natural astaxanthin (algae-derived) · Synthetic astaxanthin · Astaxanthin esters · Astaxanthin mono-/diesters · AstaREAL / BioAstin-style algal products (brand family talk) · 3S,3'S astaxanthin

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Non-peptide Niche talk Systemic Oral; topical minority Antioxidant & performance adjacents

Systemic oral fat-soluble xanthophyll carotenoid (C40H52O4); lipoprotein-carried plasma exposure with tissue lag for skin/eyes/muscle.

What people say Astaxanthin is a red-orange, fat-soluble carotenoid, usually taken as an oral algal soft-gel for skin, eye-comfort or recovery goals. It is not a peptide; trial outcomes and everyday impressions are mixed. Doses people talk about
General oral discussion4–6 mg once daily

Lower 2–4 mg tolerance-testing reports coexist; broad research summaries span 2–12 mg/day and sometimes 6–20 mg/day.

Skin-focused studies / logs6–12 mg/day

Multi-week oral use; 6 mg cosmetic-study and 12 mg comparison contexts, not a universal skin dose.

Eye-strain research4–9 mg/day

Broader summaries quote 4–12 mg with a fat meal for at least 4–8 weeks.

Exercise / recovery studies4–24 mg/day

Includes 12 mg/day four-week work and 20–24 mg experimental arms; results vary by protocol.

These are study and community descriptions, not a dose ladder. Oleoresin mg and astaxanthin mg are different; 40 mg/day short-term and 100 mg single-meal research are not routine targets.

Half-life & effect duration

Half-life in the body
  • 100 mg with a meal · study meanAbout 21 hours
  • 100 mg-equivalent diester · study meanAbout 52 hours
  • Other plasma summariesAbout 18 hours or about 32 hours, depending on study and formulation
  • Red-blood-cell estimateAbout 28 hours
Felt duration people report
  • Positive accountsChanges within days; dry-eye improvement at 8 days in one account
  • Other accountsNo noticeable benefit over years or during weeks off
  • After stoppingInsomnia or tiredness resolved in one account; timing unspecified
Timing context & sources
How it may feel Often little is felt. Some report skin or dry-eye changes within days to weeks; others notice no benefit even with long use. GI changes, reddish stool and occasional sleep complaints also appear.
Cycles people discuss Skin/eye checks often use 6–12 weeks; exercise studies span 1–4 or 4–12 weeks. Community use can continue for months or years, with seasonal changes and optional breaks—not a standard washout. Timing Once daily with a fat-containing meal is the usual discussion, with breakfast or dinner both used. Oil matrix and food affect absorption; a plasma peak hours later is not a promised time to feel it. Stacks Eye blends pair it with lutein/zeaxanthin. Community trays describe 4–12 mg astaxanthin with 1–3 g EPA+DHA, or ubiquinol around 100 mg; these are co-use habits, not proven synergy or fixed ratios. Watch for Warfarin / INR case report: Published case: astaxanthin added to warfarin associated with INR rise to >10 and bleeding/bruising complications — major red-flag interaction narrative for anticoagulant users.
Related
CoQ10

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

One 100 mg meal study measured a mean plasma half-life of about 21 hours.

The estimate was 21 ± 11 hours with Tmax 6.7 ± 1.2 hours. A separate 100 mg-equivalent diester study measured unesterified plasma astaxanthin and reported 52 ± 40 hours.

Tiny cohorts and high single doses; neither estimate is a validated clock for every 4–12 mg retail algal soft-gel. The ± figures describe reported variability, not a universal dosing interval.

Felt duration people report

There is no reliable per-capsule felt window in the checked reports.

Accounts include changes within days or dry-eye improvement at 8 days, no discernible benefit after years, no change during weeks off, and insomnia/tiredness resolving after stopping without a precise interval.

Uncontrolled recall and co-use; course length and symptom resolution do not measure parent clearance or prove causation.

Other context in this card

What people say 16

  • Stack halo: Often credited inside omega-3 + ASX fish-oil combos, eye carotenoid stacks, or “longevity multivitamin” blends — attribution is confounded. forum
  • Community skin/resilience logs: Long-term biohack users (often 8–12 mg daily for months–years) report sun-resilient or “better recovering” skin more often than dramatic vision fixes; many report no obvious subjective change. forum
  • Skin moisture & elasticity: Oral ~6 mg/day multi-week blocks (often 6–8 weeks, sometimes to 12–16) associated with improved moisture, elasticity, and wrinkle parameters in several cohorts; 12 mg sometimes discussed as stronger on inflammation-linked skin endpoints than 6 mg in dose-comparison work. trial
  • Oral + topical combo: Classic open-label design ~6 mg oral daily plus topical ASX (e.g., ~1–2 mL cream twice daily) for ~8 weeks reported wrinkle-depth, age-spot, texture, and moisture improvements — multi-route confound remains. trial
  • Male skin RCT signal: ~6 mg oral vs placebo ~6 weeks improved elasticity, wrinkles, and TEWL markers in men in at least one controlled arm. trial
  • UV / photoaging adjacency: Oral trials discuss reduced UV-induced erythema and better barrier/moisture markers over weeks — not a substitute for SPF. trial
  • Digital eye strain / VDT fatigue: ~4–9 mg/day (broader doctor-summary band ~4–12 mg) for ~4–12 weeks improved visual-fatigue and accommodation-related markers in screen-heavy adults; 6 mg is a frequently cited single-dose study level; 12 mg discussed for far-acuity/choroidal-flow signals in some reports. trial
  • Mild dry-eye: Some clinical work notes improved mild–moderate dry-eye symptom scores — does not replace ophthalmology care. trial
  • Eye multi-nutrient stack trial: Example multi-ingredient capsule set delivering ~4 mg ASX + ~10 mg lutein + ~50 mg DHA (plus bilberry/soy hull extracts) for 4 weeks improved near-point accommodation and subjective VDT symptoms vs placebo — single-agent ASX credit is limited. trial
  • Exercise recovery / DOMS (mixed): 12 mg/day × ~4 weeks reduced subjective DOMS after eccentric work in resistance-trained men in one interventional report (~50–60% less soreness at 24–48 h on some scales in AstaReal-branded writeups); other RCTs at 8–12 mg × 4 weeks found null effects on CK, soreness, or inflammation after EIMD or long runs. trial
  • Team-sport / soccer signal: ~4 mg/day for ~90 days attenuated CK/ROS and supported antioxidant status in young soccer players in published work. trial
  • Endurance performance (mixed): Short-term 12 mg/day (~7 days) reported better 40-km cycling time or longer TTE with lower exercise-induced CK/LDH/MDA in some trials; other arms (e.g., 20 mg × 28 days in trained cyclists, or some 4-week protocols) showed no performance or substrate-use benefit. trial
  • Oxidative-stress biomarkers: Lower lipid-peroxidation and higher antioxidant-enzyme talk across metabolic and exercise contexts; anti-inflammatory pathway discussion is common but not universal across RCTs. trial
  • Cognitive minority signal: Small RCTs ~6–12 mg/day for ~8–12 weeks in midlife adults with forgetfulness complaints reported modest CogHealth/maze or word-recall shifts — not nootropic consensus and sample sizes are limited. trial
  • Blood-pressure adjacency: Meta/summary talk of small diastolic BP reductions (sometimes noted more in Asian cohorts) — caution frame, not a hypertension therapy claim. trial
  • Animal models: Rodent papers cite endurance, muscle redox, and organ-protection endpoints at mg/kg doses not directly transferable to human soft-gel math. animal

Doses people talk about 18

  • General / starter community band: ~4–6 mg once daily is a common “basic” starting range on labels and forums; some start 2–4 mg to test GI tolerance. forum
  • Split vs once-daily: Once daily with the largest fat-containing meal is a prominent reported pattern. Writers invoke the longer plasma half-life to explain why split or multi-hourly dosing is less discussed, not as proof that one interval is optimal. forum
  • MCT / oil co-ingest talk: Vendors and absorption notes pair ASX with MCT, olive oil, egg yolk, or fish-oil soft-gels to leverage chylomicron transport — practical stack habit more than a fixed ratio protocol. forum
  • Natural esters vs synthetic free form: Algal mono-/diesters (3S,3'S) are preferred in community and much positive human-trial material; synthetic free racemate is cheaper/aquafeed-linked. The cited laboratory comparison favored natural N-AX over synthetic S-AX, not the reverse: roughly 20× stronger free-radical elimination and over 50× stronger singlet-oxygen quenching. This industry-linked in-vitro comparison does not establish human outcome superiority or a dose-conversion ratio. forumlab
  • Food context (not a dose substitute): Sockeye salmon and similar can supply low-single-digit mg per serving; biohack users still use soft-gels when targeting study-range daily totals. forum
  • WebMD/label-style natural vs synthetic split: Secondary consumer sources sometimes list synthetic ~2 mg/day “safe” talk vs natural algal ~2–8 mg/day — conflicts with many natural-ASX trials at 6–12 mg; treat as conservative consumer guidance, not a single global rule. forum
  • Oleoresin vs pure-mg confusion: Some labels list mg of Haematococcus oleoresin; actual ATX content is a fraction (EU mapping often assumes oleoresin strength such that 40–80 mg oleoresin ≈ ≤8 mg ATX). Always read “mg astaxanthin,” not only “mg extract.” forum
  • Uncertainty flag: Oil matrix, ester profile, isomer mix, oxidation state, and true labeled free-equivalent mg drive plasma rise more than brand hype; third-party testing is uneven. forum
  • Broad human study band: Most clinical work uses ~2–12 mg oral free-equivalent astaxanthin per day; Examine-style summaries often note ~6–20 mg/day as the frequently reported supplemental band for up to ~12 weeks. trial
  • Skin-focused range: ~6–12 mg/day for multi-week anti-aging/skin blocks; 6 mg is the classic single-arm cosmetic-study dose; 12 mg appears in dose-comparison and higher-ambition skin talk. trial
  • Eye-strain / VDT range: ~4–9 mg/day in many visual-display fatigue study contexts; clinician-facing summaries often quote 4–12 mg with a fat meal for ≥4–8 weeks. trial
  • Exercise / recovery band: Protocols span ~4 mg/day (longer soccer-season style) through 12 mg/day (4-week DOMS and some short endurance loading) to experimental 20–24 mg arms; results are mixed by dose and protocol. trial
  • Higher experimental / short-term studied band: Doses up to ~40 mg/day for up to ~12 weeks appear in safety summaries as used without serious AEs in studied settings; single-meal PK work has used ~100 mg in small volunteer cohorts — not standard daily biohack practice. trial
  • With dietary fat (critical): Take with a fat-containing meal or oil soft-gel matrix; empty stomach markedly weakens carotenoid uptake. Comparative formulation talk cites ~1.7–3.7× bioavailability for lipid systems vs reference and ~2–4× better absorption with fat meals vs low-fat/fasted in secondary summaries. trial
  • Micellar / enhanced-delivery products: PK comparison work: micellar ASX reached higher Cmax sooner (~3.7 h vs ~8.5 h native) with similar ~32 h elimination half-life — product-specific, not universal. trial
  • Smoking interaction with exposure: Examine research notes ~40% lower bioavailability-related exposure in smokers (peripheral/metabolic context), which feeds “smokers may need more careful expectations” talk — not a dose-doubling protocol. trial
  • Framing: Discussed community, label, and trial ranges only — research/educational context, not medical advice or individualized prescriptions. forum
  • Regulatory / safety reference points: EFSA novel-food opinion: up to 8 mg ATX/day from food supplements considered safe for adults (with diet exposure); EU oleoresin authorization historically maps 40–80 mg oleoresin/day to ≤8 mg ATX. FDA GRAS-context talk often cites ~6–7 mg daily in secondary sources. These are safety/authorization frames, not efficacy targets. trial

How it may feel 8

  • Acute / first impressions: It is not generally discussed as a stimulant or pre-workout pump. Plasma peaks hours after oral dosing are not a felt-effect clock. One 12 mg gel-cap user noticed skin/workout changes within days and possible libido reduction while explicitly questioning placebo/nocebo. forum
  • Days 1–7: Some feel nothing; others note mild GI effects (loose stool, stomach discomfort) or orange-red stool from the pigment. The checked discussions do not establish a majority response rate. forum
  • Weeks 1–2: This is an early observation window in daily-use logs, not the point when absorption first begins. Skin/eye changes may still be subtle or absent; one user described dry-eye improvement after 8 days. forum
  • Weeks 3–4: Common first community checkpoint for “screen-eye less fried” or early skin-glow notes; matches shorter VDT and some skin observation windows. forum
  • Months 3–6+: Long continuous daily use is common in longevity/skin stacks; experience is usually background support rather than escalating subjective intensity. forum
  • No change / later updates: Older discussion after about 6–8 weeks questions empty-stomach use, very low-fat meals, synthetic versus natural source, oxidized soft-gels, labeled mg and skincare/sleep confounders; these are proposed explanations, not proof of a correctable cause. One 12 mg daily user reported no discernible benefit over about 10 years and no change during a few weeks off, then resumed less regularly; a later update said they were still off. Another reported insomnia/tiredness that stopped after discontinuation, without a precise offset interval. forum
  • Weeks 6–12: Standard published window for multi-week skin, eye, and several exercise/DOMS protocols; “fair trial” language in forums clusters here. trial
  • Weeks 4–8: Aligns with many published skin open-label/RCT and digital-fatigue blocks (often 4–8 weeks minimum doctor-summary framing). trial

Cycles people discuss 8

  • Continuous daily use is default: Treated as an ongoing daily oral supplement (like omega-3 or CoQ10), not a short pulsed peptide or on/off SARM-style cycle. forum
  • Long-term open use: Multi-month to multi-year continuous daily use appears in biohack anecdotes (e.g., 8–12 mg for years); formal lifelong outcome data remain limited. forum
  • Seasonal / UV / travel pulses: Some raise toward the upper common band (e.g., toward 12 mg) around high-sun seasons, ski/beach trips, or heavy outdoor training — not a standardized medical schedule. forum
  • Time-off / washout: Pauses for budget, bloodwork experiments, or to A/B skin and eye subjective difference; no consensus mandatory washout or PCT-like protocol. forum
  • Re-starts after gaps: Community accounts describe resuming the prior daily amount with food, with less ritual than GHS/SARM restarts. This is a reported habit, not a restart instruction. forum
  • Load then maintain (minority pattern): Occasional community pattern of a few weeks at 12 mg then step down to 4–6 mg maintenance — not trial-standardized. forum
  • Trial-length “fair trial” blocks: 6–12 weeks is the informal minimum many users and protocols use before judging skin or eye goals; exercise studies often 1–4 weeks load or 4–12 weeks. trial
  • Combination products duration: Long-term multi-ingredient use (ASX + other carotenoids/vitamins) at lower ASX (e.g., ~4 mg) for up to ~12 months appears in safety summaries. trial

Timing 9

  • Why daily dosing is discussed: Multi-hour-to-day plasma exposure and tissue distribution are invoked to explain once-daily oral habits and above-baseline exposure. Those PK observations do not validate an optimal individual schedule; this is not weekly-depot formulation evidence. trialforum
  • With-meal timing preference: With the largest fat-containing meal (breakfast or dinner both used); superior AM-vs-PM outcome data are limited — consistency + fat matters more than clock time in community practice. forum
  • Tissue lag for goals: Skin appearance, eye comfort, and recovery changes — if they occur — track over weeks of cumulative exposure, not minutes after a capsule. anecdote
  • Storage-linked potency loss: Light/heat accelerate degradation of carotenoid soft-gels — apparent “non-response” can be oxidized product rather than true biological non-response. forum
  • Plasma elimination half-life (human, formulation-specific): Older summaries cluster roughly 16–32 hours. In three men after a single 100 mg isomer-mixture meal, Tmax was 6.7 ± 1.2 hours and plasma elimination t½ 21 ± 11 hours. A separate diester study in three men reported 52 ± 40 hours after the 100 mg equivalent dose, measuring circulating unesterified astaxanthin; it was not the same cohort or formulation. Other retained summary figures are about 18 hours plasma / 28 hours RBC and about 32 hours for micellar versus native products. These are different studies/analytes, not one universal retail-soft-gel range. trial
  • Tmax practical window: Native soft-gels often peak ~6–9 hours post-dose; enhanced micellar products may peak earlier (~3–4 h in one comparison). Meal composition changes the curve. trial
  • Lipoprotein carriage: Post-absorptive ASX distributes into VLDL/chylomicron, LDL, and HDL fractions — fat-soluble transport story behind with-meal advice. trial
  • Super-dose persistence talk: Secondary research summaries note small doses (~10 mg) can remain detectable ~a day and very large single doses (~100 mg) longer (~72 h context) — still not a reason for infrequent mega-dosing as standard practice. trial
  • Low-fat / fasting risk: Fasting or very low-fat meals cut carotenoid micellarization and uptake; taking “on empty for better absorption” is the wrong habit for this molecule. trial

More on what it is 8

  • Why people use it: Premium “membrane antioxidant” narrative for skin glow, screen-eye fatigue, recovery, and longevity stacks next to CoQ10, omega-3s, and lutein/zeaxanthin. forum
  • Research lens: Always check labeled mg of free-equivalent astaxanthin vs oleoresin weight, oil matrix, with-fat instructions, natural vs synthetic source, and whether endpoints match the goal (skin vs eyes vs DOMS). forum
  • What it is: Red-orange keto-carotenoid concentrated in Haematococcus pluvialis microalgae and in salmon/shrimp/krill flesh; most human-supp talk means algal oleoresin soft-gels, not a drug. trial
  • Mechanism talk: Spans bilayers; discussed as singlet-oxygen quencher and radical scavenger without becoming a damaging pro-oxidant as readily as some carotenoids — mechanism is often oversimplified in marketing. trial
  • Natural vs synthetic debate: Natural H. pluvialis material is mostly esterified (3S,3'S); synthetic is free/non-esterified racemic ~1:2:1 (3S,3'S : 3R,3'S meso : 3R,3'R). Bro and vendor lore strongly prefers natural esters; head-to-head outcome superiority in humans is not fully settled. trial
  • Evidence posture: Multiple human RCTs/open-label arms on skin moisture-elasticity-wrinkle metrics, visual-display fatigue, and some exercise markers at roughly 4–12 mg/day for weeks to months; longevity and disease-treatment claims remain thin or unsupported. trial
  • What it is not: Not a peptide, SARM, steroid, or FDA-approved therapy to reverse aging, cure eye disease, or replace sunscreen/clinical care. trial
  • Sparse-honesty flag: High-talk antioxidant brand does not equal high-certainty ergogenic or nootropic status — null and mixed exercise trials exist at 8–20 mg. trial

Stacks 9

  • Omega-3 co-ingest (most practical stack): ASX soft-gel with fish oil / krill / algae EPA-DHA at the same meal — fat vehicle + complementary inflammation/eye narratives. Community often pairs ~4–12 mg ASX with ~1–3 g combined EPA+DHA, but this is habit stacking not a fixed clinical ratio. forum
  • Skin stack: Oral ASX with collagen peptides, vitamin C, hyaluronic acid, or topical retinoids/SPF — multi-factor confound; oral+topical ASX combo is the research-adjacent version. forum
  • Longevity / mitochondrial adjacency: CoQ10 or ubiquinol (~100 mg ubiquinol appears in public biohacker stack lists), PQQ, NMN/NR, and omega-3s in “antioxidant longevity” trays — evidence for synergy is mostly theoretical/marketing. forum
  • Vitamin E family caution/stack talk: Tocopherols/tocotrienols sometimes co-listed as fat-soluble antioxidant partners; high-dose vitamin E has its own risk profile — not free stacking. forum
  • Training recovery tray: With creatine, adequate protein, sleep hygiene, and anti-inflammatory diet habits; ASX is not a replacement for progressive overload recovery basics. forum
  • Curcumin + ASX + omega-3: Commercial “triple” anti-inflammatory oils exist (example products deliver low single-digit mg ASX per serving with fish oil and curcumin) — doses of ASX in food-oils are often below standalone study targets. forum
  • Fat co-ingest rule as stack: Egg yolks, olive oil, MCT, avocado, or the soft-gel’s own oil are treated as absorption co-factors more than optional extras. forum
  • What people usually do not stack it as: Not typically part of Wolverine/GLOW/KLOW peptide blends or research-chem inject stacks; stays in oral nutraceutical lane. forum
  • Classic eye stack: ASX + lutein + zeaxanthin (and often meso-zeaxanthin) for screen-eye / macular-carotenoid talk; trial example multi-ingredient set used ~4 mg ASX + ~10 mg lutein + ~50 mg DHA. Ratios vary widely by product. trial

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 15

  • Broader bleeding / antiplatelet caution: Secondary sources extend caution to other anticoagulants/antiplatelets (e.g., heparin, aspirin talk) based on possible mild blood-flow/antiplatelet effects — evidence beyond the warfarin case is thinner. forum
  • Hormone / calcium / endocrine caution lists: Consumer monographs sometimes flag low blood calcium, osteoporosis, parathyroid disorders, and hormone-sensitive conditions as precaution categories — often poorly referenced; treat as “discuss with clinician,” not proven ASX endocrinology. forum
  • Diabetes / autoimmune / hypertension lists: Some hospital monographs dump broad “use caution” lists without strong mechanistic trials — sparse primary evidence; still part of community risk-check culture. forum
  • Statins / cholesterol-drug interaction talk: Occasional secondary lists mention atorvastatin/simvastatin-type caution without robust interaction RCTs — low-confidence but searched. forum
  • Pregnancy / lactation: High-dose supplemental safety not established; food-level intake from seafood is a different exposure context. forum
  • Source quality & oxidation: Natural vs synthetic, ester content, stereo-isomer mix, heavy-metal/algae contaminants, and heat/light oxidation vary by vendor — cheap oxidized soft-gels undermine both safety assumptions and efficacy expectations. forum
  • Allergy: Shellfish/algae sensitivity is occasionally discussed for certain extracts; true ASX allergy appears uncommon but product matrices differ. forum
  • Generally well tolerated at common bands: Short-term use at ~4–12 mg/day (and studied use up to ~40 mg/day for up to ~12 weeks in safety summaries) is usually described as well tolerated without serious AEs in trial aggregates; “well tolerated” ≠ risk-free. trial
  • GI effects: Increased bowel movements, loose stool, stomach discomfort or pain — more often noted at higher totals or sensitive stomachs. trial
  • Stool color: Orange-red or reddish stool from the pigment is common and expected; not GI bleeding by itself but can confuse users. trial
  • Skin tint (high intake talk): Prolonged very high carotenoid intake can theoretically tint skin; human reports of clinically obvious carotenodermia at standard 4–12 mg are rare; animal high-dose color change is not a direct human parallel. trial
  • Blood pressure: Small diastolic BP reductions appear in summaries; caution if baseline hypotension or concurrent antihypertensives (additive dizziness/hypotension talk). trial
  • Warfarin / INR case report: Published case: astaxanthin added to warfarin associated with INR rise to >10 and bleeding/bruising complications — major red-flag interaction narrative for anticoagulant users. trial
  • Children / adolescents: EFSA exposure math is more restrictive for younger age bands historically; adult biohack dosing should not be casually applied to kids. trial
  • Not risk-free longevity insurance: Good short-term tolerability and antioxidant marketing do not prove disease prevention, lifespan extension, or safety of mega-dose chronic use beyond studied windows. trial

Updated: 2026-08-12

Evidence mix More trial/lab tags than forum tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →